ReviewReviews in medical virology2021
The unique features of SARS-CoV-2 transmission: Comparison with SARS-CoV, MERS-CoV and 2009 H1N1 pandemic influenza virus.
Review in Reviews in medical virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 113 citations in OpenAlex.
- Learning from the covid-19 outbreaks in long-term care facilities: a systematic review.BMC geriatrics · 2023Pooled it
- Comparative analysis of inflight transmission of SARS-CoV-2, influenza, and SARS-CoV-1.Epidemiology and infection · 2023Pooled it
- Imported SARS-CoV-2 Infections at N'djili International Airport in Kinshasa, Democratic Republic of Congo: An Epidemiological and Genomic Analysis.Influenza and other respiratory viruses · 2026Article
- The Effect of Naturally Acquired Immunity on Mortality Predictors: A Focus on Individuals with New Coronavirus.Biomedicines · 2025Article
- The strategy to control the outbreak of an emerging respiratory infectious disease in a simulated Chinese megacity.Heliyon · 2025Article
- From pandemics to preparedness: harnessing AI, CRISPR, and synthetic biology to counter biosecurity threats.Frontiers in public health · 2025Review
- Investigation of the genome, taxonomy, and distribution of pigeon gammacoronavirus: insights into its relationships with other avian gammacoronaviruses.Frontiers in microbiology · 2025Article
- Towards a Comprehensive Definition of Pandemics and Strategies for Prevention: A Historical Review and Future Perspectives.Microorganisms · 2024Review
- Nanoarchitectonics for synergistic activity of multimetallic nanohybrids as a possible approach for antimicrobial resistance (AMR).Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2024Review
- Polypropylene-Rendered Antiviral by Three-Dimensionally Surface-Grafted Poly(ACS applied materials & interfaces · 2024Article
- Two Receptor Binding Strategy of SARS-CoV-2 Is Mediated by Both the N-Terminal and Receptor-Binding Spike Domain.The journal of physical chemistry. B · 2024Article
- Immunologic and inflammatory consequences of SARS-CoV-2 infection and its implications in renal disease.Frontiers in immunology · 2024Review
- A novel N95 respirator with chitosan nanoparticles: mechanical, antiviral, microbiological and cytotoxicity evaluations.Discover nano · 2023Article
- Bibliometric analysis of publication trends and topics of influenza-related encephalopathy from 2000 to 2022.Immunity, inflammation and disease · 2023Article
- PCovNet+: A CNN-VAE anomaly detection framework with LSTM embeddings for smartwatch-based COVID-19 detection.Engineering applications of artificial intelligence · 2023Article
- The relationship between controllability, optimal testing resource allocation, and incubation-latent period mismatch as revealed by COVID-19.Infectious Disease Modelling · 2023Article
- Virus Inactivation Based on Optimal Surfactant Reservoir of Mesoporous Silica.ACS applied bio materials · 2023Article
- Repurposing a SARS-CoV-2 surveillance program for infectious respiratory diseases in a university setting.Frontiers in public health · 2023Article
- Assessment of transmissibility and measures effectiveness of SARS in 8 regions, China, 2002-2003.Frontiers in cellular and infection microbiology · 2023Article
- The role of machine learning in health policies during the COVID-19 pandemic and in long COVID management.Frontiers in public health · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
From 2002 to 2019, three deadly human coronaviruses (hCoVs), severe acute respiratory syndrome coronavirus (SARS-CoV), Middle Eastern respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged to produce outbreaks of SARS, MERS and coronavirus disease 2019 (Covid-19), respectively. All three hCoVs are members of the Betacoronavirus genus in the subfamily Orthocoronavirinae and share many similarities in virology and epidemiology. However, the pattern and scale of Covid-19 global spread is similar to 2009 pandemic H1N1 influenza (H1N1pdm09), rather than SARS or MERS. Covid-19 exhibits high viral shedding in the upper respiratory tract at an early stage of infection, and has a high proportion of transmission competent individuals that are pre-symptomatic, asymptomatic and mildly symptomatic, characteristics seen in H1N1pdm09 but not in SARS or MERS. These two traits of Covid-19 and H1N1pdm09 result in reduced efficiency in identification of transmission sources by symptomatic screening and play important roles in their ability to spread unchecked to cause pandemics. To overcome these attributes of Covid-19 in community transmission, identifying the transmission source by testing for virus shedding and interrupting chains of transmission by social distancing and public masking are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.